Andrei H Iagaru

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Mol Imaging Biol 14:252-9. 2012
  2. ncbi Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma
    Andrei Iagaru
    Stanford University Medical Center, Division of Nuclear Medicine, Stanford, CA 94305, USA
    Hell J Nucl Med 12:26-9. 2009
  3. ncbi 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
  4. ncbi F-18 FDG PET visualization of urinary leak after nephrostomy tube removal
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 32:168-9. 2007
  5. ncbi FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
  6. ncbi (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305 5427, USA
    Hell J Nucl Med 11:153-6. 2008
  7. ncbi 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008
  8. ncbi Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, LosAngeles, Calif, USA
    J Nucl Cardiol 13:719-21. 2006
  9. ncbi PET/CT follow-up in nonossifying fibroma
    Andrei Iagaru
    Keck School of Medicine, University of Southern California, PET Imaging Science Center, Los Angeles, CA, USA
    AJR Am J Roentgenol 187:830-2. 2006
  10. ncbi F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, VA Palo Alto Health Care System, Stanford, California 94305, USA
    Clin Nucl Med 31:476-8. 2006

Detail Information

Publications32

  1. ncbi Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Mol Imaging Biol 14:252-9. 2012
    ..There are few prospective studies comparing these three methods of detection of skeletal metastases. Thus, we were prompted to initiate this prospective pilot trial...
  2. ncbi Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma
    Andrei Iagaru
    Stanford University Medical Center, Division of Nuclear Medicine, Stanford, CA 94305, USA
    Hell J Nucl Med 12:26-9. 2009
    ..The emergence of the combined PET/CT scanner enhanced the accuracy of the imaging procedure in view of the precise anatomic localization of metabolic abnormalities...
  3. ncbi 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
  4. ncbi F-18 FDG PET visualization of urinary leak after nephrostomy tube removal
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 32:168-9. 2007
  5. ncbi FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
    ..e., eyes to thighs) may yield little additional information. Therefore, we were prompted to review our experience with PET/computed tomography (CT) in the management of patients with HNSCC and NPC...
  6. ncbi (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305 5427, USA
    Hell J Nucl Med 11:153-6. 2008
    ..80 in group B. Results of PET/CT after 2 cycles of chemotherapy did not statistically differ from the results of PET/CT after 4 cycles of chemotherapy. These results need to be confirmed in larger, prospective, randomized trials...
  7. ncbi 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008
    ..Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma...
  8. ncbi Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, LosAngeles, Calif, USA
    J Nucl Cardiol 13:719-21. 2006
  9. ncbi PET/CT follow-up in nonossifying fibroma
    Andrei Iagaru
    Keck School of Medicine, University of Southern California, PET Imaging Science Center, Los Angeles, CA, USA
    AJR Am J Roentgenol 187:830-2. 2006
  10. ncbi F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, VA Palo Alto Health Care System, Stanford, California 94305, USA
    Clin Nucl Med 31:476-8. 2006
  11. ncbi 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 49:1809-12. 2008
    ..90Y-ibritumomab is an antibody targeting CD20 receptors on the surface of lymphocytes. We present observations from our clinical experience with 90Y-ibritumomab in the management of NHL...
  12. ncbi F-18 FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, VA Palo Alto Health Care System, Stanford, CA 94305, USA
    Clin Nucl Med 31:279-80. 2006
  13. ncbi Demonstration of a right inguinal hernia containing urinary bladder diverticulum on whole-body bone scan and pelvic CT
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, 300 Pasteur Dr, Room H-0101, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 33:234. 2006
  14. ncbi Failed atrial septal defect repair versus pulmonary hypertension with right ventricular failure
    Andrei Iagaru
    Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Nucl Med 30:767-8. 2005
  15. ncbi Perspectives of molecular imaging and radioimmunotherapy in lymphoma
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305 5427, USA
    Radiol Clin North Am 46:243-52, viii. 2008
    ..Finally, we discuss advances in molecular imaging that may herald the next generation of PET radiotracers after 18F FDG...
  16. ncbi Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography
    Daniel Y Sze
    Division of Interventional Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Hum Gene Ther 23:91-7. 2012
    ..More sophisticated molecular imaging will need to be developed to monitor the effects of this novel class of antineoplastic agents...
  17. ncbi F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Stanford Hospital and Clinics, Stanford, California, USA
    Clin Nucl Med 31:754-60. 2006
    ..However, CT had a better detection rate for pulmonary metastases when compared with PET alone. A negative PET scan in the presence of suspicious CT findings in the chest cannot reliably exclude pulmonary metastases from OSTS...
  18. ncbi Thyroid stunning: fact or fiction?
    I Ross McDougall
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, CA, USA
    Semin Nucl Med 41:105-12. 2011
    ..Larger diagnostic doses and longer delays to therapy appear to increase the likelihood of stunning. The stunning effect of early-absorbed radiation from the therapy should also be considered...
  19. ncbi Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging ?(v)?(3) integrin levels
    Erik S Mittra
    Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Dr, Room H2200, Stanford, CA 94305 5281, USA
    Radiology 260:182-91. 2011
    ....
  20. ncbi Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California, USA
    J Nucl Med 50:501-5. 2009
    ..Sodium (18)F was previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of (18)F and (18)F-FDG in a single PET/CT study for cancer detection has not been reported to date...
  21. ncbi F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, Los Angeles, CA 90033, USA
    Clin Nucl Med 33:8-13. 2008
    ..A review of our experience with PET in assessing therapy response in osseous and soft tissue sarcomas (OSTS) is presented...
  22. ncbi FDG PET-CT demonstration of Sjogren's sialoadenitis
    Hossein Jadvar
    Department of Radiology, Division of Nuclear Medicine, PET Imaging Science Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 30:698-9. 2005
    ..CT transmission scan was obtained for attenuation correction. PET-CT demonstrated no evidence of hypermetabolic nodal disease but showed symmetric intensely hypermetabolic submandibular and parotid salivary glands...
  23. ncbi F-18 FDG PET/CT in the management of thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Nucl Med 32:690-5. 2007
    ..We reviewed our experience with F-18 FDG PET/CT in thyroid cancer, with an emphasis on correlation with Tg, and maximum standardized uptake values (SUV). We also analyzed the role of thyroid stimulating hormone (TSH) on PET/CT results...
  24. ncbi Advances in metabolic imaging for surgical oncology
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305, USA
    Surg Oncol Clin N Am 16:273-92. 2007
    ..Finally, advances in molecular imaging that may herald the next generation of PET radiotracers beyond (18)F FDG are reviewed...
  25. ncbi 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, Los Angeles, CA 90033, USA
    Nucl Med Commun 27:795-802. 2006
    ..Sub-centimetre CT lesions should not be considered false positive if inactive on PET. A negative PET scan in the presence of suspicious CT findings in the chest cannot reliably exclude pulmonary metastases from OSTS...
  26. ncbi Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT
    Andrei Iagaru
    PET Imaging Science Center, Department of Radiology, University of Southern California, Keck School of Medicine of USC, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    Mol Imaging Biol 9:72-7. 2007
    ..However, controversies exist regarding its ability to reliably assess recurrent medullary thyroid cancer (MTC). We were therefore prompted to review our experience with FDG-PET for detection of occult MTC...
  27. ncbi F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Clin Nucl Med 32:13-5. 2007
    ..An adrenal metastasis was identified on an F-18 FDG PET/CT scan in a patient with anaplastic thyroid cancer. There are very few reports of thyroid cancer, even anaplastic thyroid cancer, metastasizing to the adrenal...
  28. ncbi Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization
    John D Louie
    Department of Radiology, Stanford University Medical Center, CA 94305 5642, USA
    J Vasc Interv Radiol 20:606-13. 2009
    ..The present study was performed to determine if cone-beam computed tomography (CBCT) affects treatment planning as an adjunct to these conventional imaging modalities...
  29. ncbi 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, 1510 San Pablo Street, Suite 350, Los Angeles, CA, 90033, USA
    Mol Imaging Biol 8:309-14. 2006
    ..We were therefore prompted to review our experience with FDG-PET in detection of recurrent papillary thyroid cancer (PTC)...
  30. ncbi Breast MRI and 18F FDG PET/CT in the management of breast cancer
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    Ann Nucl Med 21:33-8. 2007
    ..We were therefore prompted to review our experience with PET and BMRI in BC...
  31. ncbi 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305 5427, USA
    Mol Imaging Biol 10:19-23. 2008
    ..Intraoperative gamma probe mapping of the liver identified areas with signal above the background, but these were prove to be hemosiderin deposits on histo-pathology examination...
  32. ncbi Molecular imaging can accelerate anti-angiogenic drug development and testing
    Andrei Iagaru
    Stanford University School of Medicine, Stanford, CA, USA
    Nat Clin Pract Oncol 4:556-7. 2007